Overview
INCY market data
Price History
INCY price chart
Valuation & Profitability
- P/E (TTM)
- 16.51 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $6.41 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.77 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $69.24 – $119.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $23.6K · P/B 3.75 · P/S 4.41.
Company news
JP Morgan Maintains Neutral on Incyte, Raises Price Target to $110Benzinga · Jul 23, 2026, 6:41 PM
Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $104Benzinga · Jul 23, 2026, 6:02 PM
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $140 Price TargetBenzinga · Jul 21, 2026, 10:30 AM
Halozyme Therapeutics Signs Agreement With Incyte To Mull Additional Subcutaneous Formulations Of INCA033989 Mutant Calreticulin-Targeted Monoclonal AntibodyBenzinga · Jul 20, 2026, 12:01 PM
Incyte To Present New Phase 1 Solid Tumor Data, Including KRAS G12D and TGFβR2×PD‑1 Programs, At ESMO 2026Benzinga · Jul 17, 2026, 5:12 PM
Barclays Maintains Overweight on Incyte, Raises Price Target to $134Benzinga · Jul 14, 2026, 11:04 AM
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood DisorderBenzinga · Jul 13, 2026, 1:25 PM
BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $112Benzinga · Jul 13, 2026, 12:57 PM
Incyte Presents Phase 1/2 Multidose Data For VGA039 (Latarcibart) At ISTH 2026, Showing 81% Median Reduction In Annualized Bleeding Rate Across All Von Willebrand Disease Types And Bleed CategoriesBenzinga · Jul 13, 2026, 8:08 AM
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $99Benzinga · Jul 7, 2026, 3:45 PM